High Court To Weigh In On Amgen Class Cert. Quarrel

Law360, New York (June 11, 2012, 11:50 AM EDT) -- The U.S. Supreme Court on Monday agreed to hear an appeal of a Ninth Circuit decision that kept intact a shareholder class alleging Amgen Inc. misled investors about the safety of two top-selling anemia drugs, accusations Amgen says are based on statements that weren't material.

In a brief order, the high court granted Amgen's petition of a writ of certiorari to hear the appeal of the Ninth Circuit's November 8 decision. Justice Stephen Breyer recused himself from the certiorari decision, the order said.

The Ninth Circuit...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.